BLA resubmitted to FDA for denileukin diftitox in relapsed/refractory cutaneous T-cell lymphoma – Citius Pharmaceuticals
The biologics license application (BLA) for the interleukin (IL)-2–based immunotherapy denileukin diftitox (Lymphir) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least 1 prior… read more.
